ARTICLE | Clinical News
Cell Pathways to test Aptosyn with Xeloda
February 2, 2000 8:00 AM UTC
CLPA will conduct a dose ranging Phase I trial to determine the safety of Aptosyn exisulind in combination with Roche's Xeloda capecitabine to treat breast and colon cancer. The combination is in Phas...